

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of this ILP sub-fund and complements the Prospectus¹ and Product Summary.
- It is important to read the Product Summary and Prospectus before deciding whether to purchase units in the ILP sub-fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP sub-fund if you do not understand it or are not comfortable with the accompanying risks.

Baillie Gifford Worldwide Health Innovation Fund – Class A USD

| | | | |
|---|--|---------------------------------------|--|
| Product Type | ILP sub-fund ² | Launch Date | 21 March 2022 |
| ILP sub-fund manager | Baillie Gifford Investment Management (Europe) Limited | Depository | Brown Brothers Harriman Trustee Services (Ireland) Limited. |
| Trustee | Not applicable | Dealing Frequency | Every Pricing Day |
| Capital Guaranteed | No | Expense Ratio as at 30 September 2023 | Class A USD: 1.65% |
| Name of Guarantor | Not applicable | | |
| ILP SUB-FUND SUITABILITY | | | |
| WHO IS THE ILP SUB-FUND SUITABLE FOR? <ul style="list-style-type: none">• The ILP sub-fund is <u>only</u> suitable for investors who:<ul style="list-style-type: none">○ seeking a fund that aims to deliver capital growth over a long term investment horizon with a thematic focus on investing in companies that have the potential to bring substantial improvements to human health, lengthen lifespans and reduce healthcare costs in a method that evidences care about patients.○ is prepared to bear losses; and○ is not concerned about short-term volatility and performance, not seeking a regular source of income and not investing for less than five years. <p>Please note the ILP sub-fund does not distribute dividend and where applicable will re-invest the dividend (if any) received from the Underlying Fund.</p> <p>An investment in the ILP sub-fund should not constitute a substantial proportion of an investment portfolio.</p> <p>Investors should consult authorized financial advisers if in doubt whether this product is suitable for them. This ILP Sub-Fund feeds into a restricted scheme, which is a fund/ unit trust only available to, amongst others, accredited investors in Singapore. You should consider the investment risks stated in this document and consult your financial adviser to confirm if the fund is suitable for your risk profile.</p> | | | Further Information Please refer to the “Target Market Information” section of the Underlying Fund’s Prospectus for further information on the suitability of the Sub-Fund. |
| KEY FEATURES OF THE ILP SUB-FUND | | | |
| WHAT ARE YOU INVESTING IN? <p>You are investing in an ILP sub-fund which feeds 100% into the Baillie Gifford Worldwide Health Innovation Fund - Class A USD (the “Underlying Fund”), a sub-fund of Baillie Gifford Worldwide Funds plc. Baillie Gifford Worldwide Funds plc is an open-ended investment company with variable capital organised under the laws of Ireland as a public limited company pursuant to the Companies Acts and the UCITS Regulations and is organised in the form of an umbrella fund with segregated liability between sub-funds.</p> | | | Please refer to the “Introduction” section of the Underlying Fund’s Prospectus for further information on features of the Sub-Fund. |
| Investment Strategy | | | |
| <ul style="list-style-type: none">• The Underlying Fund’s objective is to provide strong returns over the long term by investing primarily in a global equity portfolio selected from companies engaged in the healthcare industry and that promotes better healthcare outcomes by driving real | | | Please refer to the “Investment Objectives and Policies of the Funds” section of the |

¹The Prospectus is available, through Us or through the Manager’s website at <https://bailliegifford.com/en/singapore>

² For ILP sub-fund that feeds 100% into an underlying CIS fund, some of the information provided below could be similar to the underlying CIS fund.

| | |
|--|--|
| <p>change for patients and the healthcare system and evidence care about patients. The Underlying Fund may also invest in other transferable securities, money market instruments, cash and cash equivalents.</p> <ul style="list-style-type: none"> • The Underlying Fund will seek to achieve its objective primarily through investment in a portfolio which is concentrated in the number of its stocks but diversified across a range of healthcare themes. • The investment strategy of the Fund is to invest at least 90 per cent. of its Net Asset Value in global equities selected from companies involved in the healthcare industry and which are innovative in their focus on areas such as diagnostics, treatment and prevention and contribute to solving a problem for the healthcare system in a method that cares about its patients. The Fund will not be restricted to equity securities in the healthcare sector as defined by any particular index. • The Underlying Fund will not invest more than 10% of its net asset value in units or shares of eligible collective investment schemes, including exchange traded funds • The Underlying Fund may invest in currency forwards to reduce currency risk but not to take active positions on currency. Such use will be for efficient portfolio management purposes. • The Underlying Fund may only use financial derivative instruments for efficient portfolio management purposes. | <p>Underlying Fund's Prospectus for further information on the investment strategy.</p> |
| Parties Involved | |
| <p>WHO ARE YOU INVESTING WITH?</p> <ul style="list-style-type: none"> • Investment-Linked Plan Provider is Etiqa Insurance Pte. Ltd. • The ILP sub-fund manager is Baillie Gifford Investment Management (Europe) Limited • The Depositary of the Underlying Fund is Brown Brothers Harriman Trustee Services (Ireland) Limited. | <p>Please refer to the "Management and Administration" section of the Underlying Fund's Prospectus and the "Information on the Custodian" section in the Investment-Linked Pricing of Units, a supplement to Product Summary for further information on the role and responsibilities of these entities.</p> |
| KEY RISKS | |
| <p>WHAT ARE THE KEY RISKS OF THIS INVESTMENT?</p> <p>Investment markets can go down as well as up and market conditions can change rapidly. The value of an investment in the Underlying Fund, and any income from it, can fall as well as rise and you may not get back the amount invested.</p> | <p>Please refer to the "Risk Factors" section of the Underlying Fund's Prospectus for further information on the key risks.</p> |
| Market and Credit Risks | |
| <p>You are exposed to investment risk. There can be no assurance that the Underlying Fund will achieve its investment objective. An investment in the Underlying Fund involves investment risks, including possible loss of the amount invested. Therefore, the Underlying Fund's returns may be expected to fluctuate in response to changes in capital appreciation or income. Consequently, the investment is suitable only for investors who are in a position to take such risks and to adopt a long-term approach to their investment strategy.</p> <p>You are exposed to political risks. The performance of the Underlying Fund may be affected by changes in economic and market conditions, uncertainties such as political developments, military conflict and</p> <p>You are exposed to currency risks. The Underlying Fund has exposure to foreign currencies and changes in the rates of exchange will cause the value of any investment, and income from it, to fall as well as rise and you may not get back the amount invested.</p> | |

| | | | |
|---|-----------------------|-----------------|--|
| <p>You are exposed to force majeure risks. Infectious viruses may pose significant threats to human health and may be highly disruptive to global economies and markets. The economic and market disruptions caused by infectious viruses could impact the value of the investments of the Underlying Fund.</p> | | | |
| Liquidity Risks | | | |
| <p>Some of the markets, exchanges or securities in which the Underlying Fund may invest may prove to be less liquid than developed markets and prices may be highly volatile from time to time. This may affect the price at which and the time period in which the Underlying Fund may liquidate positions to meet redemption requests or other funding requirements.</p> <p>The Underlying Fund is not listed. There is no secondary market for the Underlying Fund.</p> | | | |
| Product-Specific Risks | | | |
| <p>You are exposed to custody risks. Custody of assets, particularly in emerging markets, involves a risk of loss if a custodian becomes insolvent or breaches duties of care.</p> <p>You are exposed to emerging markets risk. The Underlying Fund invests in emerging markets where difficulties in trading could arise, resulting in a negative impact on the value of your investment.</p> | | | |
| FEES AND CHARGES | | | |
| <p>WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?</p> <p>You will need to pay the following fees and charges.</p> <p><u>Payable directly by You</u></p> <p>There are no ILP sub-fund charges which are directly payable. For the full charges of the investment-linked policy you are invested in, please refer to the relevant product summary which will be made available to you. We may introduce new fees or charges; or increase or decrease existing fees and charges by providing you with at least 30 days' notice.</p> <p><u>Payable by the ILP sub-fund from invested proceeds</u></p> <p>The ILP sub-fund will pay the following fees and charges to the fund manager, ILP sub-fund manager, Trustee and other parties:</p> <table border="1" data-bbox="247 1339 1093 1377"> <tr> <td>Management Fee</td><td>1.50% per annum</td></tr> </table> <p>These fees and charges are not guaranteed. We may change the fees and charges or introduce new fees and charges as long as they will not exceed the maximum limit stated in the Product Summary or Fund Factsheet. We will give You written notification thirty (30) days before We make the change.</p> | Management Fee | 1.50% per annum | <p>Refer to section "Fees and Charges" stated in Product Summary for more information.</p> |
| Management Fee | 1.50% per annum | | |

| VALUATIONS AND EXITING FROM THIS INVESTMENT | | | | | | | | | |
|---|--|---------------------------|---------------------------|-------------------------|-------|-----------|----------|----------|--|
| <p>HOW OFTEN ARE VALUATIONS AVAILABLE?</p> <p>Valuations are available on each Business Day. The subscription and redemption prices are published in www.etiqa.com.sg.</p> <p>HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?</p> <ul style="list-style-type: none">• You may exit (“realise”) your units wholly or in part by submitting a realization form to the relevant financial adviser or Us. Partial realisations are subject to minimum holding requirements.• You may return this policy for cancellation within fourteen (14) days after You receive the policy document, for any reason. We will refund You the Premiums You have paid less any change in the unit price(s) of the Portfolio Fund / ILP Sub-Fund and any costs incurred by Us in assessing the risk under the policy, such as payments for medical check-up and other expenses. Any partial withdrawal(s) previously paid to You under this policy will also be deducted.• Should the free look and/or redemption request be received before 3 p.m. (Singapore time), the request will be taken to have been received on that Business Day and we will place your order on the next Business Day, subject to the ILP sub-fund manager’s pricing policy. If you miss the cut-off time or on a day which is not a Business Day, the request will be taken to have been received on the next Business Day and we will place your order two Business Day later, subject to the ILP sub-fund manager’s pricing policy.• The following example illustrates the amount of redemption proceeds You will receive based on a redemption of 1,000 units and a notional redemption price of S\$0.95*: <table><tr><td>Number of units to be Redeemed</td><td>Redemption Price</td><td>Gross Redemption Proceeds</td><td>Net Redemption Proceeds</td></tr><tr><td>1,000</td><td>X S\$0.95</td><td>= S\$950</td><td>= S\$950</td></tr></table> <p>* The actual redemption price of the units will fluctuate according to the net asset value of the units.</p> | Number of units to be Redeemed | Redemption Price | Gross Redemption Proceeds | Net Redemption Proceeds | 1,000 | X S\$0.95 | = S\$950 | = S\$950 | <p>Refer to “Pricing and Dealing Deadlines”, “Settlement for Redemption” and “Free Look Period” stated in Product Summary for further information.</p> |
| Number of units to be Redeemed | Redemption Price | Gross Redemption Proceeds | Net Redemption Proceeds | | | | | | |
| 1,000 | X S\$0.95 | = S\$950 | = S\$950 | | | | | | |
| CONTACT INFORMATION | | | | | | | | | |
| <p>HOW DO YOU CONTACT US?</p> <p>You may email Us at customer.service@etiqa.com.sg or contact Our Etiqa Customer Care Hotline +65 6887 8777</p> <p>Customer Service Centre: One Raffles Quay, #22-01 North Tower, Singapore 048583</p> <p>Monday – Friday, 8.30am – 5.30pm (excluding Public Holidays)</p> | | | | | | | | | |
| APPENDIX: GLOSSARY OF TERMS | | | | | | | | | |
| ILP | : means investment linked policy. | | | | | | | | |
| We / Our / Us | Etiqa Insurance Pte. Ltd. (Company Registration No. 201331905K). | | | | | | | | |
| You / Your | : Life Insured | | | | | | | | |